4/A
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-081748
Chief Operating Officer sold 40,000 shares at an average $35.09 ($1,403,668)
- Chief Operating Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Option exercise 10b5-1 | +29,787 | $5.54 | $165,020 | 178,579 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Sale 10b5-1 | −29,787 | $35.01 | $1,042,843 | 148,792 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Option exercise 10b5-1 | +10,213 | $5.54 | $56,580 | 159,005 | D |
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Sale 10b5-1 | −10,213 | $35.33 | $360,825 | 148,792 | D |
| Derivatives | |||||||
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-21 | Option exercise · Stock option (right to buy) 10b5-1 | −29,787 | 70,699 | D | ||
| HIGH SUSANNA GATTI Chief Operating Officer | 2024-06-24 | Option exercise · Stock option (right to buy) 10b5-1 | −10,213 | 60,486 | D | ||
| Open-market sales · 40,000 sh · avg $35.09 · $1,403,668 | |||||||
Loading xslF345X05/ownership.xml…